[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc filed a Form 6-K reporting a notification of transactions by persons discharging managerial responsibilities (PDMRs) under the UK Market Abuse Regulation. The notice, dated 26 September 2025, discloses a transaction price of £3.31963. The filing lists the company’s well-known brands including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren and directs readers to the corporate website. The report provides the required public disclosure of insider activity but does not include clear aggregated volume figures in the provided text, limiting assessment of the transaction’s size or investor impact.

Positive

• Regulatory disclosure complied with via a PDMR notification dated 26 September 2025
• Specific transaction price disclosed at £3.31963, enabling price-level transparency

Negative

• Aggregated volume not provided in the visible text, preventing assessment of transaction size
• Limited detail in filing (no identification code or clear instrument description present) which restricts investor analysis

Insights

Corporate Governance Analyst

TL;DR: The filing is a routine PDMR trade notice showing a price but lacking clear volume data.

The document confirms compliance with disclosure rules by reporting transactions by PDMRs and gives a specific transaction price of £3.31963 on 26 September 2025

Key dependency is the missing aggregated volume: without volume the market impact and insider exposure cannot be measured. Watch for a follow-up notice or regulatory filing that supplies the traded volumes or aggregated totals within short reporting windows.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	26 September 2025- “Director/PDMR Shareholding”

99.1

Haleon plc: Director/PDMR Shareholding

​

​26 September 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

On 25 September 2025, the Company was notified of the following transactions as detailed below.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dawn Allen
2	Reason for the notification
a)	Position/status	Chief Financial Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument   Identification code	Ordinary Shares of £0.01 each GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares as a result of dividend reinvestment
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.31963	1186.71154
	d)	Aggregated information	N/A
- Aggregated volume
- Price
e)		Date of the transaction	23 September 2025
f)		Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Keith Choy
2	Reason for the notification
a)	Position/status	President, Asia Pacific - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	GB00BMX86B70
	b)	Nature of the transaction	Acquisition of Ordinary Shares as a result of dividend reinvestment
	c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.31963	3749.41677
d)		Aggregated information	N/A
	- Aggregated volume
	- Price
	e)	Date of the transaction	23 September 2025
	f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Filippo Lanzi
2	Reason for the notification
a)	Position/status	President, EMEA and LATAM - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument   Identification code	Ordinary Shares of £0.01 each GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares as a result of dividend reinvestment
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.31963	2356.42498
	d)	Aggregated information	N/A
- Aggregated volume
- Price
e)		Date of the transaction	23 September 2025
f)		Place of the transaction	London Stock Exchange (XLON)

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian McNamara

2

Reason for the notification

a)

Position/status

Chief Executive Officer - PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Haleon plc

b)

LEI

549300PSB3WWEODCUP19

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument   Identification code

Ordinary Shares of £0.01 each GB00BMX86B70

b)

Nature of the transaction

Acquisition of Ordinary Shares as a result of dividend reinvestment

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£3.31963

5693.56923

d)

Aggregated information

N/A

- Aggregated volume

- Price

e)

Date of the transaction

23 September 2025

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument   Identification code

Haleon plc American Depositary Shares (ADS) US4055521003

b)

Nature of the transaction

Acquisition of ADSs as a result of dividend reinvestment

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$8.99986

2026.50806

d)

Aggregated information

N/A

- Aggregated volume

- Price

e)

Date of the transaction

23 September 2025

f)

Place of the transaction

New York Stock Exchange (XNYS)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Edward Petter
2	Reason for the notification
a)	Position/status	Chief Corporate Affairs Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument   Identification code	Ordinary Shares of £0.01 each GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares as a result of dividend reinvestment
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.31963	576.54018
	d)	Aggregated information	N/A
- Aggregated volume
- Price
e)		Date of the transaction	23 September 2025
f)		Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tamara Rogers
2	Reason for the notification
a)	Position/status	Chief Marketing Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument   Identification code	Ordinary Shares of £0.01 each GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares as a result of dividend reinvestment
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.31963	1906.13339
	d)	Aggregated information	N/A
- Aggregated volume
- Price
e)		Date of the transaction	23 September 2025
f)		Place of the transaction	London Stock Exchange (XLON)

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 26, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLN) disclose in the Form 6-K dated 26 September 2025?

The filing disclosed a PDMR (insider) transaction with a reported price of £3.31963 and listed company brands; it served as the public notification required under the UK Market Abuse Regulation.

Does the filing state how many shares were traded for the HLN transaction?

No. The visible text does not provide an aggregated volume or clear number of shares, so the traded quantity is not disclosed here.

Is the transaction date identified for the Haleon PDMR notice (HLN)?

Yes. The notice is dated 26 September 2025, and the Company was notified of the transactions on 25 September 2025.

What price per share was reported for the Haleon PDMR trade?

The filing reports a transaction price of £3.31963.

Where can investors find more information about Haleon (HLN)?

The filing directs readers to the corporate website at www.haleon.com for additional company information.